The efficacy and toxicity of the CHG priming regimen (low-dose cytarabine, homoharringtonine, and G-CSF) in higher risk MDS patients relapsed or refractory to decitabine

ConclusionsThe CHG priming regimen provided a safe and effective salvage regimen for higher risk MDS patients who were resistant to decitabine. Further studies involving larger samples will be needed. Clinical trial No. ChiCTR-ONC-11001501.

http://link.springer.com/10.1007/s00432-019-03031-w

Source: Journal of Cancer Research and Clinical Oncology - November 18, 2019 Category: Cancer & Oncology Source Type: research